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DOI 10.1016/j.ccr.2009.11.019SUMMARYChronic lymphocytic leukemia (CLL) is a malignancy of B cells of unknown etiology. Deletions of the chromo-
somal region 13q14 are commonly associated with CLL, with monoclonal B cell lymphocytosis (MBL), which
occasionally precedes CLL, and with aggressive lymphoma, suggesting that this region contains a tumor-
suppressor gene. Here, we demonstrate that deletion in mice of the 13q14-minimal deleted region (MDR),
which encodes the DLEU2/miR-15a/16-1 cluster, causes development of indolent B cell-autonomous, clonal
lymphoproliferative disorders, recapitulating the spectrum of CLL-associated phenotypes observed in
humans. miR-15a/16-1-deletion accelerates the proliferation of both human and mouse B cells by modu-
lating the expression of genes controlling cell-cycle progression. These results define the role of 13q14 dele-
tions in the pathogenesis of CLL.INTRODUCTION
B cell chronic lymphocytic leukemia (CLL) represents the most
common B cell-derived malignancy of adults with an incidence
of around 1 in 100,000 per year. The disease is characterized
by the clonal expansion of B cells that express the CD5 cell
surface antigen and that are thought to derive from antigen-
experienced marginal zone B cells (Chiorazzi and Ferrarini,
2003; Klein et al., 2001). Within this morphologically homoge-
neous tumor, two subtypes of CLL have been identified: one
that expresses somatically mutated immunoglobulin variable
region (IgV) genes and has a good prognosis, and one withSIGNIFICANCE
Emerging evidence has suggested the presence of a tumor-su
deleted in CLL. These results show that this region has a major
Its deletion causes a heterogeneous B-cell-autonomous phe
syndromes including MBL and lymphoma. Within the 13q14-
the proliferation of B cells, but additional genetic elements invar
of the phenotype. These results elucidate the mechanism by w
model of human CLL, and provide a paradigm for the tumor-s
28 Cancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc.unmutated IgV genes and a less favorable prognosis (Chiorazzi
and Ferrarini, 2003; Damle et al., 1999; Hamblin et al., 1999).
Recent work suggests that CLL may be preceded by CD5+
monoclonal B cell lymphocytosis (MBL), which is detectable in
5% of the healthy elderly population and that can progress to
CLL in 1% of cases (Landgren et al., 2009; Rawstron et al.,
2008). A small fraction of CLL progresses toward a more aggres-
sive malignancy diagnosed as diffuse large B cell lymphoma
(DLBCL).
The pathogenesis of CLL remains obscure because no genetic
alteration has been conclusively demonstrated to contribute to
its pathogenesis. Although CLL only rarely shows reciprocalppressor locus in the chromosomal region 13q14 commonly
role in controlling the pool of mature B-lymphocytes in vivo.
notype that recapitulates the spectrum of CLL-associated
region, the miR-15a/16-1 cluster plays a role in controlling
iably deleted in humanCLL contribute to the aggressiveness
hich miR-15a/16-1 function in vivo, provide a faithful mouse
uppressor role of sterile RNA transcripts.
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesisbalanced chromosomal translocations (Do¨hner et al., 2000;Mayr
et al., 2006), the spectrum of genomic aberrations in CLL
includes trisomy of chromosome 12 (16%) and deletion of chro-
mosomal regions 17p (p53; 7%), 11q (18%), and 13q14.3 (further
on designated as 13q14), which represents the most common
genomic aberration in CLL (55%) (Do¨hner et al., 2000; Kalachi-
kov et al., 1997). Inactivation of p53 is observed in a fraction of
cases and is associated with disease progression (Gaidano
et al., 1991).
Deletion of 13q14 is mostly monoallelic (76% of cases), but
can be biallelic (24%) (Do¨hner et al., 2000). This deletion occurs
in CLL with somatically mutated as well as unmutated IgV genes,
although it is more prevalent in the former subtype (80% versus
20%). 13q14 deletions are found at high frequency (>50%) also
in MBL (Rawstron et al., 2008) and at lower frequency in CD5-
negative B cell-derived malignancies (Avet-Loiseau et al.,
1999; Cigudosa et al., 1998; Liu et al., 1995; Stilgenbauer
et al., 1998), including DLBCL and multiple myeloma, as well
as mature T cell lymphomas (Rosenwald et al., 1999), and in
a variety of solid tumors.
Because 13q14 deletions suggest the presence of a tumor-
suppressor gene, this region has been extensively characterized
(Bullrich et al., 2001; Corcoran et al., 1998; Liu et al., 1997;
Migliazza et al., 2001; Rondeau et al., 2001; Stilgenbauer et al.,
1998). A minimal deleted region (MDR) has been identified (Liu
et al., 1997; Migliazza et al., 2001) that comprises the deleted
in leukemia (DLEU) 2 gene, encoding a sterile transcript, parts
of the DLEU1 (1st exon) sterile gene, as well as the microRNA
(miR)-15a/16-1 cluster (Calin et al., 2002; Lagos-Quintana
et al., 2001) that is located intronic to DLEU2 (see Figure 1A).
Although DLEU2 and the miRs are evolutionary conserved and
expressed in B cells (Cimmino et al., 2005; Mertens et al.,
2002; Migliazza et al., 2001), a role of DLEU1 as well as the
adjacent DLEU5 and KCNRG genes (Ivanov et al., 2003) in CLL
pathogenesis is considered unlikely based on lack of evolu-
tionary conservation (DLEU1), inclusion in only a subset of
13q14 deletions (DLEU5,KCNRG), and low to absent expression
in mature B cells (KCNRG). Taken together, these observations
pointed toward DLEU2 and/or miR-15a/16-1 as the candidate
tumor suppressors targeted by 13q14 deletions in CLL.
DLEU2 encodes a long noncoding RNA (1.0–1.8 kb) that is pol-
yadenylated and spliced (Migliazza et al., 2001). Members of this
class of sterile RNAs exert diverse cellular functions including
X chromosome inactivation or activation, imprinting, and tran-
scriptional coactivation or regulation of gene expression (Pont-
ing et al., 2009). The function of DLEU2, however, is unknown,
and its sequence does not display homology to any other non-
coding RNA. A role for miR-15a/16-1 in CLL pathogenesis has
been repeatedly proposed based on in vitro studies in nonlym-
phoid cell systems that suggested functions of miR-15a/16-1
in negative regulation of proliferation and apoptosis (Bandi
et al., 2009; Calin et al., 2008; Cimmino et al., 2005; Linsley
et al., 2007; Liu et al., 2008; Raveche et al., 2007). Also, CLL
cases were identified (2%) that showed germline mutations in
the primary precursor of miR-15a/16-1 that appear to affect its
processing (Calin et al., 2005), and a point mutation occurring
in the 30 flanking region ofmiR-16-1 in NZB mice has been asso-
ciated with reduced miR-16-1 expression (Raveche et al., 2007).
Downregulation of miR-15a/16-1 has also been implicated in thepathogenesis of prostate carcinoma (Bonci et al., 2008). Based
on these observations, the miR-15a/16-1 cluster has been sug-
gested as the culprit of the deletion in CLL, but no formal proof
has been obtained.
In order to identify the genetic elements targeted by the puta-
tive 13q14 tumor suppressor and to determine their contribution
to CLL pathogenesis, we generated transgenic mice that carried
conditional alleles that either mimicked the deletion of the MDR
or that specifically deleted the miR-15a/16-1 cluster without
affecting the expression of DLEU2.
RESULTS
Construction ofMice Deleting theMDR ormiR-15a/16-1
The 13q14 region is conserved on mouse chromosomal region
14qC3 (Figure 1A). In contrast to the human genome, Kcnrg
and dLeu5 are intronic of and overlap with dLeu2, respectively,
although rare splice forms have been described for DLEU2 in
the human that also overlap with those genes (Baranova et al.,
2003). Analogous to the human genome, the miR-15a/16-1
cluster is located intronic of the dLeu2 gene 300 bp down-
stream of exon 4 (Figure 1A bottom). To investigate the conse-
quences of the deletion of the genes encoded within the 13q14
MDR, we generated conditional mouse alleles that upon Cre-
or Flpe-mediated deletion either mimic the human MDR and
delete both dLeu2 and miR-15a/16-1 (further on referred to as
conditional MDR allele), or the miR-15a/16-1 cluster only.
To generate the conditional MDR allele, we inserted two loxP
as well as two frt sites in consecutive ES cell targetings into
transcriptionally silent regions that are located 110 kb apart
(Figure 1B; for details of the targeting, see Figures S1A1 and
S1A2, available online) with the 50 site located approximately
20 kb centromeric to dLeu5, and the 30 site about 5 kb telomeric
to the alternative exon 1 (exon 1b) of dLeu2. To allow screening
for ES cell clones where both targetings occurred on the same
chromosome, an eGFP mini gene and a PGK promoter were
placed in the centromeric and telomeric targeting vectors,
respectively, thus enabling eGFP expression upon Adeno-Cre-
mediated deletion of the loxP-flanked MDR. Correct homolo-
gous recombination of the individual targetings and correct
Cre-mediated deletion of the loxP-flanked region were con-
firmed by Southern blot analysis (Figure S1A4 and Figure 1B,
lower right). Mice carrying the MDRloxP-frt/+ allele were bred
with Flp-transgenic mice, and the deletion of the frt-flanked
region was confirmed by Southern blotting (Figure S1A3 and
Figure 1B lower left); these mice are further on referred to as
MDR+/ mice.
The conditionalmiR-15a/16-1 allele was generated by placing
the first loxP-site centromeric to the miR-15a/16-1 cluster and
the second one within the 400 bp region that separates the
miR cluster and exon 4 of dLeu2 (Figure 1C; for details of the
targeting see Figure S1B1). Correct homologous recombination
was confirmed by Southern blot analysis (Figure S1B1). The
neo-resistance marker was deleted by crossing mice with the
targeted allele to Flp-transgenic mice, further on designated as
miR-15a/16-1fl/+ (conditional) mice (Figure S1B2). Mice carrying
the conditional allele were bred with Cre-transgenic mice, and
deletion of the loxP-flanked region was confirmed by Southern
blot (Figure 1C and Figure S1B2); these mice are further onCancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc. 29
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Figure 1. Deletion of the 13q14-MDR and of miR-15a/16-1 in Mice
(A) Schematic representation of the human 13q14 andmouse 14qC3 locus. Genes and their 50-30 orientation are indicated by thick arrows.MDR, minimal deleted
region.
(B) Schematic representation of theMDR targeting strategy; for details, see Figures S1A1–S1A4. Indicated are the expected fragments detected by Southern blot
analysis after (bottom left) Flp-mediated recombination in mice which generates anMDR null allele, and after (bottom right) Adeno-Cre-mediated recombination
inMDRfl/+ embryonic stem cells (ESCs), which shows a DloxP fragment besides the targeted fragment, demonstrating the feasibility of deleting the 120 kb condi-
tional MDR allele.
(C) Schematic representation of themiR-15a/16-1 targeting strategy. Correct deletion ofmiR-15a/16-1 was identified by Southern blot analysis of PstI-digested
DNA that displayed the 3.5 kB deleted band along with the 6.9 kB wild-type (WT) band (right) as indicated in the targeting strategy. For details, see Figure S1B1
and S1B2.
(D) dLeu2 mRNA is normally expressed in miR-15a/16-1/ B cells. RT-PCR from purified CD19+ B cells with oligonucleotides hybridizing in exon 2 (forward
primer) and exon 5 (reverse primer) of dLeu2 showed the expected 430 bp band in all genotypes, demonstrating that the deletion of the miR-15a/16-1 cluster
localized in intron 4 of the dLeu2 gene does not affect the correct splicing of the dLeu2 transcript.
(E) Deletion of the loxP-flanked MDR allele in vivo. Southern blot analysis of SpeI-digested DNA from purified CD19+ B cells of MDRfl/+CD19-Cre and MDRfl/+
mice. MDRfl/+ CD19-Cre mice show the WT allele and the allele after loxP-mediated deletion.
(F) Deletion of the loxP-flanked miR-15a/16-1 allele in vivo. PCR analysis from purified CD19+ and CD19 B cells. CD19-enriched B cells from miR-15a/16-1fl/+
CD19-Cre mice have theWT allele and the allele obtained after loxP-mediated deletion, whereas those frommiR-15a/16-1fl/+ mice show the loxP-flanked and the
WT allele; the faint loxP-deleted band in the CD19-negative miR-15a/16-1fl/+CD19-Cre fraction is due to cellular contamination of B cells.
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesisreferred to as miR-15a/16-1+/ mice. Reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis of purified CD19+
splenic B cells for dLeu2 confirmed that normal dLeu2 mRNA
expression was not perturbed in mice with a homozygous dele-
tion of miR-15a/16-1 (Figure 1D). The conditional miR-15a/16-1
allele was confirmed to express physiological amounts of the
miRs (Figure S1B3). To generate age-matched cohorts of
MDR- or miR-15a/16-1-homozygous, heterozygous, and wild-
type littermates, we intercrossed the F1 generation of MDR+/30 Cancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc.or miR-15a/16-1+/ mice. Both genotypes yielded homozygous
mice at the expected Mendelian frequencies.
CD5+ B Cell Expansion inMDR/ andmiR-15a/16-1/
Mice
Mice of both recombinant genotypes developed normally and
macroscopic and microscopic analysis showed that nonlym-
phoid organs including heart, lung, liver, kidney, and intestine
of MDR/ or miR-15a/16-1/ mice were normal. At young
>30
0
4
8
12
16
20
24
11.2% 8.8%1.1%
MDR
–/–WT miR–/–
B220
C
D
5
miR-15a/16-1
P=0.02
P=0.02
%
C
D
5+
B
22
0l
o
>30
0
4
8
12
16
20
24
MDR
P=0.06
P=0.04
–/– +/– +/+ –/– +/– +/+
n=      42            52             42 n=     31             29             22
A
B
Figure 2. CD5+ B Cell Expansions in PB of
Mice with Deletion ofMDR ormiR-15a/16-1
(A) Flow cytometry of PB mononuclear cells from
a miR-15a/16-1/, an MDR/, and an age-
matched WTmouse for CD5 and the B cell marker
B220. The two former mice display a distinct
CD5+B220lo population that does not occur in
WT mice.
(B) Percentages of CD5+B220lo cells among
mononuclear cells of mice from MDR and miR-
15a/16-1 cohorts; ‘‘n’’ refers to the number of
mice analyzed, p values (t test) are indicated; the
dotted line demarks the upper threshold for the
normal range of CD5+B220lo cells in a panel of
3- to 6-month-old WT mice determined by the
average percentage ± 3s; percentages above
4% are considered CD5+ lymphocytosis. Data
are shown both as actual values (filled circles)
and as mean and standard deviation (± SD).
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesisage (2–4 months), homozygous MDR/ and miR-15a/16-1/
mice showed normal percentages of B cell and T cell subpopu-
lations and normal development of lymphoid organs (Figure S2A
and data not shown). Immunization of 2- to 3-month-oldMDR/
mice with a T cell-dependent antigen showed no differences in
the percentages of the responding cell types, including germinal
center (GC) B cells, IgG1+ memory B cells, and plasma cells
(Figure S2B). Together, these results suggest that homozygous
deletion of the MDR or miR-15a/16-1 does not impair lympho-
cyte development in young mice. However, at 12 months of
age,MDR/ mice showed higher percentages of CD5+B220low
B cells among mononuclear cells (MNC) in the peritoneal cavity
(PerC) (50% versus 15% in controls; Figure S2C, top), which
were poly/oligoclonal by flow cytometric analysis (data not
shown). A trend toward higher fractions of PerC CD5+B220low
B cells in MDR/ mice was already detectable at 9 months.
Similar observations were made in miR-15a/16-1/ mice
(Figure S2C, bottom). Thus, deletions of the MDR and miR-
15a/16-1 are associated with expansion of CD5+B220low cells
in the PerC, suggesting that the MDR locus has a role in regu-
lating the pool of mature CD5+ B cells.
Deletion ofMDR ormiR-15a/16-1 Leads to MBL
With increasing age (15–18 months), flow cytometric analysis of
various MNC populations in the peripheral blood (PB) revealed
that MDR/ and miR-15a/16-1/ mice frequently developed
aCD5+B220low population in the PB (Figure 2A), whichwas shown
to be clonal by PCR amplification and direct sequencing of rear-
ranged IgV genes (Table S1). This population accounted for
8% and 4% of PBMC inMDR/ andmiR-15a/16-1/ mice,Cancer Cell 17, 28–4respectively (Figure 2B). At lower pene-
trance, the same phenotype was detect-
able also in both MDR and miR-15a/16-1
monoallelic-deleted mice, although the
difference compared with wild-type mice
did not reach statistical significance.
These results demonstrate that deletion
of the MDR or miR-15a/16-1 promotes
the development of clonal lymphocytosisin the PB, which in a percentage of cases was restricted to the
PB analogous to humanMBL. Approximately 5%of bothMDR/
andmiR-15a/16-1/mice developed MBL (see Figure 4A).
Development of CLL and Non-Hodgkin Lymphoma
in MDR andmiR-15a/16-1-Deleted Mice
In a fraction ofmice, clonal CD5+ B cell populations were accom-
panied by significant infiltration of lymphoid organs, as detected
by flow cytometry and/or Southern blot analysis for IgH rear-
rangements, with histopathologic features resembling human
CLL/small cell lymphocytic leukemia (SLL) (Figure 3). These
mice displayed an enlargement of the splenic white pulp due
to the expansion or accumulation of small lymphocytes, with
a pattern similar to CLL/SLL (Figure 3 and Figure S3A). The PB
smear displayed abundant small lymphocytes and numerous
‘‘smudge cells’’ characteristic of human CLL (Figure 3 bottom)
Discrete aggregates of small lymphocytes could also be
observed in the bone marrow (Figure S3A). Southern blot anal-
ysis demonstrated that these lymphoproliferations were clonal
(Figure S3B). Overall, 27% of MDR/ and 21% of miR-15a/
16-1/ mice developed CLL/SLL (see Figure 4A).
Finally, a fraction of mice of both genotypes developed clonal
CD5-negative NHL of splenic and/or lymph node origin (9% of
MDR/, 17% of MDR+/, and 2% of miR-15a/16-1/ mice)
(Figure 3, right, Figure 4). Some of these tumors showed amature
B cell phenotype (IgM+ or Ig isotype switched, with a few staining
for GC B cell markers [peanut agglutinin, PNA]) histologically
reminiscent of human DLBCL, whereas a minority of tumors
showed plasmacytic features similar to lymphoplasmacytic
lymphoma in humans (data not shown).0, January 19, 2010 ª2010 Elsevier Inc. 31
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Figure 3. Clonal Lymphoproliferations in Mice with Deletion of MDR or miR-15a/16-1
The top row shows representative hematoxylin and eosin (H&E) stained spleen sections from MDR- or miR-15a/16-1-deleted mice presenting with MBL (from
a 15-month-old miR-15a/16-1/ mouse), CLL/SLL (from a 17-month-old MDR/ mouse), or DLBCL (from a 17-month-old MDR+/ mouse), and an age-
matched WT mouse (left). CLL/SLL: section shows enlargement of the splenic white pulp by the expansion or accumulation of small B lymphocytes with archi-
tectural andmorphologic features of CLL/SLL. DLBCL: section shows lymphoid tissuewith an infiltrate of large lymphocytes withmorphologic features of DLBCL.
The scale bar represents 1000 mm; the scale bar in the inset represents 100 mm. The second and third row show flowcytometry of splenic and PBMCcells from the
corresponding mice for CD5 and the B cell marker B220. The CLL/SLL case shows a predominant CD5+B220lo population in spleen and PB, the MBL case
demonstrates this population only in the PB. The bottom row showsWright-Giemsa stained PB smear showing an abundance of small lymphocytes and ‘‘smudge
cells’’ from a mouse diagnosed with CLL/SLL, compared with an age-matched WT mouse (left).
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DLEU2/miR-15a/16-1 Cluster in CLL PathogenesisMDR/ Mice Have a More Aggressive Disease Course
thanmiR-15a/16-1/ Mice
Altogether 42% of MDR/ and 26% of miR-15a/16-1/ 15- to
18-month-old mice developed clonal B cell lymphoprolifera-
tions, including CD5+ MBL, CLL/SLL, and NHL (Figure 4A).
MDR+/ mice too showed a trend toward developing B cell
tumors (24%), suggesting that monoallelic deletion of the MDR
can cause disease. This trend is not evident in miR-15a/16-1-
deleted mice, probably due to the lower penetrance of the
phenotype.
The event-free survival curves showed thatMDR/mice died
earlier than their wild-type littermates (p = 0.002), suggesting that
the homozygous mice eventually succumb to their tumors at an
advanced age. Conversely, the event-free survival of miR-15a/
16-1/ mice was not different from wild-type littermates, sug-
gesting that these mice show a significantly milder disease
course than their MDR counterparts (Figure 4B). In conclusion,32 Cancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc.bothMDR/ andmiR-15a/16-1/mice developed lymphopro-
liferations with an indolent disease course reminiscent of
human CLL, with theMDR/mice displaying amore aggressive
disease phenotype.
Lymphoproliferations inMDR
andmiR-15a/16-1-Deleted Mice Are B Cell Autonomous
MDR/ and miR-15a/16-1/ mice carry the respective dele-
tions in all cells, leaving open the possibility that the observed
lymphoproliferations may be due to the effect of the deletions
in non-B cells. To investigate whether the proliferations observed
in those mice developed in a B cell-autonomous fashion, we
generated mice that specifically delete either the MDR or the
miR-15a/16-1 allele in B cells by crossing MDRloxP-frt/+ or
miR-15a/16-1fl/+ mice with mice in which the Cre recombinase
is under transcriptional control of the B-lineage-restricted gene
encoding CD19 (CD19-Cre mice); these mice are further on
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Figure 4. Mice with Germline Deletion of
MDR or miR-15a/16-1 Develop Lympho-
Proliferations at Low Penetrance and
Show an Indolent Disease Course
(A) Percentages of B-lymphoid pathologies
observed in 15- to 18-month-old mice of the
MDR or miR-15a/16-1 cohorts. The percentages
of MBL, CLL/SLL, and NHL in each genotype are
color coded. ‘‘n’’ refers to the number of mice
analyzed; p values (chi-square test of association)
among the genotypes are indicated. Data are
shown both as actual values (filled circles) and
as mean ± SD. The lymphoproliferations occurred
in two independent miR-15a/16-1/ mouse lines
(data not shown).
(B) Percent event-free survival in the MDR or miR-
15a/16-1 cohorts. Mice were followed for duration
of 20 months. Events comprised mice that suc-
cumbed to illness or those identified as moribund
or sick (palpable tumor or visible ascietis) and thus
sacrificed. The p values between the different
genotypes of theMDR cohort, and those between
miR-15a/16-1 homozygous andWTmice, are indi-
cated. The number of mice of each genotype is
indicated in brackets. Mice shown in Figures 4A
and 4B corresponded to different cohorts.
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesisreferred to as MDRfl/+CD19-Cre or miR-15a/16-1fl/+CD19-Cre
mice. Southern blot or RT-PCR analysis of purified CD19+ B cells
demonstrated the ability of the conditional MDR and miR-15a/
16-1 alleles to recombine in vivo (Figures 1E and 1F).
We generated cohorts of MDRfl/CD19-Cre or miR-15a/16-
1fl/CD19-Cre mice that delete both alleles only in B cells, and
the corresponding heterozygous and wild-type controls, i.e.,
MDR+/CD19-Cre and CD19-Cre, or miR-15a/16-1+/CD19-
Cre and CD19-Cre littermates. The results demonstrated that
15-18-month-old MDRfl/CD19-Cre and miR-15a/16-1fl/
CD19-Cre mice presented with CD5+ B cell lymphocytosis in
the PB (Figure 5A), and showed the same spectrum of B cell
pathologies, at comparable frequencies, as observed in the
corresponding constitutional knock-out mice (Figure 5B). Taken
together, the results suggest that the development of clonal
lymphoproliferations in MDR- or miR-15a/16-1-deleted mice
occurred in a B cell-autonomous fashion.
Stereotypical Antigen Receptors in CD5+
Lymphoproliferations
Sequence analysis of PCR-amplified IgV genes from tumors of
homo- or heterozygous MDR or miR-15a/16-1 mice demon-
strated that CD5+ tumors expressed unmutated IgV genes,
whereas the CD5 NHLs mostly expressed somatically mutated
IgV genes (Table S1). These results suggest that lymphoprolifer-
ations in the MDR- or miR-15a/16-1-deleted mice originated
from B cells participating in T cell-independent and -dependent
antibody responses.
A distinctive feature of human CLL is the expression of struc-
turally identical or similar BCR heavy-chain complementary
determining regions 3 (HCDR3) resulting from the recombinationof the VH, DH, and JH gene segments between unrelated individ-
uals (HCDR3 ‘‘stereotypy’’ [Messmer et al., 2004; Tobin et al.,
2004; Widhopf et al., 2004]; for review see Ghia et al., 2008).
We compared the amino acid sequences of the HCDR3 regions
among the B cell tumors and observed that although the CD5
NHL cases showed highly variable HCDR3 regions (Table S2),
we could identify several clonal CD5+ B cell proliferations that
expressed IgV genes using the same VH and JH families and
in addition showed highly similar HCDR3 regions (R80%
homology at the protein level (Yan et al., 2006)) (Table 1). These
results suggest that CD5+ B cell lymphoproliferations in MDR
and miR-15a/16-1-deleted mice can express antibodies with
stereotypical antigen binding regions, suggesting a role for
common antigens or autoantigens in the clonal expansion, anal-
ogous to human CLL (Ghia et al., 2008).
miR-15a/16-1Control Proliferation inMouse andHuman
B Cells
To understand the mechanism by which the deletions lead to
clonal B-lymphoproliferations, we investigated whether miR15-
a/16-1-deletions could affect proliferation of mouse B cells, as
previously suggested for nonlymphoid cells (Bandi et al., 2009;
Calin et al., 2008; Linsley et al., 2007; Liu et al., 2008; Raveche
et al., 2007). BrdU incorporation assays, which measure
active DNA-synthesis, demonstrated that miR-15a/16-1/ B
cells begin to synthesize DNA earlier than wild-type B cells
(Figure 6A). Mitogen-stimulated B cells purified from miR-15a/
16-1/ or MDR/ and wild-type mice were analyzed for the
levels of phosphorylated retinoblastoma (p-Rb) protein, which
represents an indicator of cell cycle entry, because p-Rb cannot
repress the growth-promoting gene E2F (Weintraub et al., 1992).Cancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc. 33
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Figure 5. Mice with Deletion of MDR or
miR-15a/16-1Develop Lymphoproliferations
in a B Cell-Autonomous Fashion
(A) Percentages of CD5+B220lo cells among
mononuclear cells of 15- to 18-month-old mice
from MDR- and miR-15a/16-1-CD19-Cre cohorts;
n, number of mice analyzed; for definition of the
dotted line, see legend to Figure 2. For some
cases shown in (B), PB was not analyzed. Data
are shown both as actual values (filled circles)
and as mean ± SD.
(B) Percentages of B-lymphoid pathologies
observed in 15- to 18-month-old mice of the
MDR- or miR-15a/16-1-CD19-Cre cohorts. Mice
were sacrificed and analyzed for pathologies. The
percentages of MBL, CLL/SLL, and NHL in each
genotype are color-coded. n, number of mice
analyzed; p values (chi-square test of association)
among the genotypes were indicated if% 0.05.
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DLEU2/miR-15a/16-1 Cluster in CLL PathogenesisThe results showed that p-Rb could be detected at earlier time
points in both miR-15a/16-1/ and MDR/ compared with
wild-type B cells (Figure 6B, and Figure S4A). Consistent with
this observation, expression of the cell-cycle inhibitory protein
cyclin-dependent kinase inhibitor p27-Kip1 appeared to follow
similar kinetics (Figure 6B). Moreover, results from experiments
that determined the number of cell divisions following mitogen-
stimulation (CFSE incorporation; Figure S4B) showed that
MDR-deleted cells begin to proliferate earlier than wild-type B
cells. Of note, we did not observe differences in the proliferative
response between animals in a 129/Sv-C57BL/6 mixed and
a C57BL/6 pure background (data not shown), suggesting thatTable 1. CD5+ Lymphoproliferations from MDR,miR-15a/16-1-Deleted, or Wild-Type Mice
Animal VH VH N DH N JH
miR CD19-Cre #10 V328 A IYYGN YWYFDV
MDR CD19Cre #99 V328 AR YYSN YWYFDV
miRf CD19Cre #234 V328 AR GEK YSN YWYFDV
MDR #27 V235 MR YSN YWYFDV
MDR #138 V153 MR YGN YWYFDV
MDR CD19-Cre #197 V227 A SP NWD YWYFDV
MDR CD19-Cre #212 V186 AR NWD YWYFDV
Data forMDR,miR-15a/16-1-deleted, or wild-type mice are grouped in the following cases, respective
and #212. Cases that showedR80% amino acid sequence homology in the HCDR3 are grouped (cas
R80% homology).
34 Cancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc.the observed phenotype is not associ-
ated with a specific genetic background.
To further unravel the individual contri-
butions of DLEU2 versus the miR-15a/
16-1 cluster to the lymphoproliferative
phenotype, we generated an inducible
in vitro system in which the DLEU2
transcript and the miR-15a/16-1 cluster
were separately re-expressed in the
human I83E95 cell line that is derived
from a 13q14/ CLL (Wendel-Hansen
et al., 1994). We used an expression
vector in which a doxycycline-induciblepromoter drives the bidirectional transcription of GFP and the
inserted sequences (Figures 6C–6F). The results showed that
miR-15a/16-1-expressing cells, but not those expressing
DLEU2, were impaired in proliferation (Figure 6G). Consistent
with this observation, miR-15a/16-1-expressing cells had a
higher fraction of cells in the G0/G1 phase compared with both
DLEU2 and the control as documented by BrdU incorporation
assays (Figure 6H). Thus, expression of themiR-15a/16-1 cluster
seems to control cellular proliferation, possibly by inhibiting
the G0/G1–S phase transition. Taken together, the results of
the knock-out and re-expression experiments suggest that the
miR-15a/16-1 cluster exhibits negative control of proliferationShow Similar HCDR3 Sequences
JH CDR3 Length Diagnosis
1 12 CLL/SLL
1 12 CLL/SLL
1 14 CLL/SLL
1 11 CLL/SLL
1 11 CLL/SLL
1 11 MBL
1 10 MBL
ly: #10, #99, and #234; #27 and #138; and #197
es #10 and #99, and cases #99 and #234 show
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesisboth in human and mouse B cells. On the contrary, the DLEU2
transcript per se did not affect proliferation of 13q14-homozy-
gous deleted cells.
Identification of Potential miR-15a/16-1 Target Genes
in B Cells
Our results suggested that miR-15a/16-1may affect theG0/G1-S
phase transition in B cells (see Figure 6). We thus sought to iden-
tify candidate G0/G1-S phase-related genes among inferred
miR-15a/16-1 targets. Among those predicted by at least one
of four established computational target prediction algorithms
(miRanda, PicTar, TargetScan, and RNA22; see Experimental
Procedures), nine proteins were known to be critically involved
in the regulation of the G0/G1-S phase transition, including
cyclins CCND1, CCND2, CCND3, and CCNE1, and cyclin-
dependent kinases CDK4, CDK6, CHK1, MCM5, and CDC25A.
Three of these (CCND3, CCNE1, and CDK6) constitute verified
miR-15a/16-1 targets in nonlymphoid systems (Liu et al., 2008)
(CCND1 is not expressed in B cells and therefore not considered
here); the computational target prediction algorithms by which
the remaining miR-15a/16-1 targets were identified and the
number of potential binding sites per gene are summarized in
Table S3 (see also Figure S5; the 30UTRs of the corresponding
genes are listed in Table S4). With the exception of CDC25A,
all proteins were downregulated in I83E95 13q14/ cells upon
miR-15a/16-1 expression (Figure 7A middle, and Figure S6A).
Analogously, all gene products except Cdc25A showed higher
expression levels in anti-IgM-stimulated miR-15a/16-1-deficient
mouse B cells; of note, Ccnd2, Ccnd3, Cdk4, Cdk6, and Chk1
were upregulated faster and at markedly increased levels in
miR-15a/16-1/ versus wild-type B cells (Figure 7A middle).
Although it remains to be determined whether the proliferation-
associated genes identified represent direct or indirect miR-
15a/16-1 targets, the concurrent results obtained in two inde-
pendent genetically defined miR-15a/16-1 knock-out systems
strongly indicate that those microRNAs regulate their expres-
sion. In conclusion, the miR-15a/16-1 cluster seems to nega-
tively regulate the expression of multiple genes involved in the
G0/G1-S phase transition in both human and mouse B cells.
We also performed a supervised gene expression profile (GEP)
analysis of I83E95 cells stably transfected with miR-15a/16-1 or
empty-vector and validated the candidates at the protein level
(for details, see Supplemental Information). The results showed
additional proteins as clearly affected bymiR-15a/16-1 induction
(Figure 7A, middle, and Figure S6B; Table S3 and Figure S5),
including CCNE1 and CSE1L which are associated with cell
growth/proliferation (Behrens et al., 2003), IGF1R, an antiapop-
totic receptor (Fu¨rstenberger and Senn, 2002), and ARL2,
involved in cytokinesis (Burd et al., 2004). Interestingly, c-MYB,
which has been reported as a miR-15a/16-1 target in nonlym-
phoid cells (Zhao et al., 2009) was confirmed in this assay.
Conversely, we observed only a modest reduction of BCL2
protein (2-fold), whose regulation by miR-15a/16-1 has been
controversial (Cimmino et al., 2005; Fulci et al., 2007; Linsley
et al., 2007) (Figure 7A bottom, and Figure S6A for quantification,
see also Figure S7B). Immunohistochemical analysis of spleen
sections for BCL2 expression showed the characteristic staining
pattern with GC B cells being BCL2-negative in both wild-type
and miR-15a/16-1/ mice (Figure S7A), suggesting that amiR-15a/16-1-mediated control of BCL2-expression may have
only limited functional relevance in normal B cell physiology.
Taken together, the present findings suggest that a major role
of the tumor suppressor in chromosomal region 13q14 is the
control of cell proliferation. Specifically, deletion of the miR-
15a/16-1 cluster in B cells may accelerate the G0/G1-S phase
transition by failing to negatively regulate the expression ofmole-
cules critically involved in this transition (Figure 7B).
DISCUSSION
These results show that theDLEU2/miR-15a/16-1 locus plays an
important role in controlling the expansion of the mature B cell
pool. The mechanism by which this control is exerted is mainly
by downregulation of genes controlling cell cycle entry. The
in vivo evidence presented here corroborates and expands on
previous observations obtained in vitro mostly in non-B cells
(Bandi et al., 2009; Calin et al., 2008; Cimmino et al., 2005;
Linsley et al., 2007; Liu et al., 2008; Raveche et al., 2007), and
suggests that the DLEU2/miR-15a/16-1 locus controls B cell
expansion primarily by modulating proliferation, rather than by
influencing survival via regulation of BCL2. Importantly, despite
its expression in many tissues, the function of the DLEU2/miR-
15a/16-1 locus appears to be critical mainly for B cells because
no clearly abnormal phenotype was detectable in other cell
types. This apparent specificity may be explained by the need
to tightly modulate the entry of B cells into the cell cycle in
response to a broad range of low affinity stimulation by extrinsic
antigens and/or autoantigens. This hypothesis is supported by
the observation that DLEU2/miR-15a/16-1 expression is down-
regulated in proliferating B cells within the germinal centers
in vivo, the site where B cells are selected for the production
of antibodies with high affinity for the antigen (unpublished
observation).
These results also establish that the DLEU2/miR-15a/16-1
locus has a tumor-suppressor role in the B cell lineage in vivo,
providing a paradigm for a similar role for other sterile transcripts
in human diseases. Within this locus, one active genetic element
is clearly themiR-15a/16-1 cluster, based on its antiproliferative
effect in vitro, its targeting of cell cycle genes, and the lympho-
proliferative phenotype of miR-15a/16-1-deleted mice. How-
ever, the significantly more aggressive phenotype displayed by
the MDR-deleted mice (both in constitutionally deleted and
conditionally deleted mice) suggests that additional genetic
elements within theMDR locus contribute to the tumor suppres-
sive function. One candidate for such a role is DLEU2 itself.
Besides providing the primary transcript for the production of
miR15a/16-1, it produces a spliced cytoplasmic RNA (data not
shown) that, analogous to other long sterile transcripts (Ponting
et al., 2009), may have important regulatory functions not
detected by the in vitro assays used here. Alternatively, the
DLEU5 gene, although excluded from the MDR in humans, may
have a tumor-suppressor role in themouse,which, due to partially
overlapping loci in the mouse genome (see Figure 1A), could not
be distinguished from the one of DLEU2/miR-15a/16-1. It is,
however, important to note that 13q14 deletions are commonly
large and invariably involve the entire DLEU2/miR-15a/16-1
locus, thus suggesting that the genetic element within the MDR
that contributes to the phenotype of the miR-15a/16-1-deletedCancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc. 35
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Figure 6. miR-15a/16-1 Expression Impairs Proliferation in B Cells
(A) miR-15a/16-1/ B cells show earlier cell cycle entry than WT B cells. (Left) Representative flow cytometry of a BrdU-incorporation experiment at time point
32 hr. Cultures of anti-IgM-stimulated cells were incubated for 30 min before harvesting for BrdU/7AAD analysis. (Right) Representative time course of a BrdU-
incorporation experiment withmiR-15a/16-1/ (miR/) and WT B cells. We observed variations in the actual timing of proliferation initiation between individual
experiments.
(B)miR-15a/16-1/ B cells show faster phosphorylation of Rb protein than WT B cells. Purified B cells of the corresponding genotypes were stimulated by anti-
IgM Fab-fragments and harvested at the indicated time points. Western blots probed with an anti-p-Rb andwith an anti-Rb antibody are shown; the higher bands
in the Rb-blot correspond to phosphorylated Rb.
(C) Scheme of a vector that expresses miR-15a/16-1 or DLEU2 (exons 1–5) along with GFP from a doxycycline-inducible bidirectional promoter; transcriptional
orientation of the respective genes is indicated.
(D) Addition of doxycycline to stable cell lines containing either of the indicated genes or empty vector (EV) results in eGFP expression in the majority of cells, and
at equal percentages among the different stably transfected I83E95 cell lines, demonstrating the efficiency of the inducible system.
(E) miR-15a was selectively expressed in doxycycline-induced miR-15a/16-1-stably transfected I83E95 cells, as demonstrated by Northern blot analysis. BJAB
was included as positive control. U6 RNA was probed to test for RNA quality and equal loading of the samples.
(F) DLEU2 mRNA was selectively expressed in doxycycline-induced DLEU2-stably transfected I83E95 cells, as demonstrated by RT-PCR.
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Figure 7. Identification of miR-15a/16-1
Targets in B Cells
(A) Functional analysis for miR-15a/16-1-depen-
dent protein expression changes of putative
targets identified by (1) computationally predicted
miR-15a/16-1-targets implicated in the G0/G1-S
transition (top), (2) gene expression profiling
(GEP) (middle), and (3) the known targets c-MYB
and BCL2 (bottom), by either reintroduction of
miR-15a/16-1 into the 13q14/ human cell line
CLL-I83E95 (left), or deletion of miR-15a/16-1 in
mouse B cells (right). Fold changes in protein
expression observed upon reintroduction of miR-
15a/16-1 are indicated (left); average from two
independent experiments. The expression of
miR-15a/16-1-targets was analyzed in a time-
dependent fashion in resting (0 hr) and IgM-
stimulated proliferating mouse B cells (24 hr and
48 hr) purified from spleens of miR-15a/16-1/
mice and WT littermates (right) (representative
experiment; for quantification, see Figure S5).
Fold changes in protein expression at time
points 24 hr (top) or 48 hr (middle, bottom) are indi-
cated. The figure shows a representative b-actin
blot; for quantification, the b-actin blots of the
corresponding filters were used. Bars between Western blots indicate concordant miR-15a/16-1-dependent expression changes in human and mouse B cells.
(B) Model incorporating the results shown in Figures 6 and 7A: miR-15a/16-1 downregulate the expression of several proliferation associated proteins that have
important roles in the G0/G1-S phase transition. The absence of miR-15a/16-1 causes a faster or stronger activation of CCND2 and CCND3 as well as CDK4 and
CDK6, which are critical cell cycle checkpoints, as well as CCNE, thus leading to faster phosphorylation of Rb and hence accelerated entry into cell cycle by
activating E2F. Likewise, the E2F-regulated cell cycle-associated proteins CHK1 and MCM5 may contribute to the pro-proliferative phenotype of miR-15a/
16-1-deficient cells. miR-15a/16-1 targets are indicated by light blue ovals.
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesismice is ablated in theMDR-deleted mice. The notion thatDLEU5
may play a role in determining the lymphoproliferative pheno-
types opens the possibility that 13q14 deletions of different
size, i.e., including or excluding the DLEU5 locus, may influence
the aggressiveness of the CLL phenotype in humans.
Several features of the lymphoproliferative phenotype
observed in the MDR-deleted mice indicate that these mice
represent a remarkably faithful model of human CLL. First, this
model has been generated by recapitulating the genetic lesion
associated with the human disease. Previous mouse models of
CLL were represented by transgenic mice expressing a domi-
nantly acting oncogene (TCL1) (Bichi et al., 2002) not clearly
associated with a genetic lesion in human B cell neoplasms, or
by a mouse strain (NZB) in which the phenotype was linked to
multiple loci (Raveche et al., 2007) and the role of miR-15a/
16-1 could not be conclusively demonstrated. Second, these
mice display the full spectrum of CLL-associated phenotypes,
including MBL, the presumed low-penetrance premalignant
stage, classic CLL/SLL, and the low-penetrance aggressive
progression stage DLBCL. Third, the observed clonal CD5+
phenotypes display ‘‘stereotypic’’ Ig gene usage, a very specific
feature of human CLL that suggests an important role for
extrinsic antigens or autoantigens. Finally, the lymphoprolifera-
tive diseases displayed by the MDR-deleted mice are indolent(G) Reintroduction of miR-15a/16-1 into I83E95 cells impairs proliferation. Stabl
empty vector (EV) in a doxycyclin-dependent fashion were cultured with or witho
(H) Reintroduction of miR-15a/16-1 into I83E95 cells causes accumulation of cell
upon expression of miR-15a/16-1, DLEU2, or EVwere determined by BrdU incorp
twice; data are shown as mean ± SD.and have low penetrance, as expected for a model of human
CLL, a malignancy with a typically indolent course that is signif-
icantly more common in the elderly population. It is noteworthy,
however, that the penetrance of the phenotypes may be under-
estimated in this study because the mice have been kept in
virtually germ-free conditions, whereas antigen exposure from
various infectious agents has been repeatedly suggested as
a cofactor in CLL development. Overall, these observations indi-
cate that the mouse model described here may be useful for the
study of disease progression in CLL and as a preclinical model
for testing new therapeutic regimens for this disease.EXPERIMENTAL PROCEDURES
Generation of MDR and miR-15a/16-1 Conditional and Null Mice
For a detailed description of the transgenic mouse generation, see Figure S1
and Supplemental Experimental Procedures. In brief, two targeting vectors
were devised in order to flank the MDR with loxP and frt-sites. Successively
inserted into the cloning sites of the corresponding 50 tag and 30 tag vectors
were each twoDNA fragments of the 129/Sv-14qC3. To generate a conditional
miR-15a/16-1 allele, successively inserted into the cloning sites of the target-
ing vector were three DNA fragments of the miR-15a/16-1-locus. Chimeras
were obtained from correctly targeted ES cell colonies after injection of the tar-
geted W9.5 ES clones (129/SvEvTac) into blastocysts derived from C57BL/6
mice, and gave rise to MDRfl/+ or miR-15a/16-1fl/+ mice. The chimeras werey transfected cell lines that allow the expression of miR-15a/16-1, DLEU2, or
ut doxycycline and cell numbers were determined at the indicated time points.
s in G0/G1. Cell cycle profile and percentage of cells actively synthesizing DNA
oration/7AAD assay. The experiment shown in (G) and (H) were each performed
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DLEU2/miR-15a/16-1 Cluster in CLL Pathogenesisalso crossedwith 129/SvCAGGS-Flpe or 129/SvZip3-Cre mice (both Jackson Labo-
ratories) to generate anMDR and amiR-15a/16-1 null allele, respectively. Thus
obtained MDR+/ or miR-15a/16-1+/ mice were crossed to C57BL/6 mice,
and the resulting F1 generation was intercrossed for establishing the experi-
mental cohort. Likewise, MDRfl/+ or miR-15a/16-1fl/+ mice were bred with
C57BL/6 mice; those mice were intercrossed with CD19-Cre. In vivo deletion
of the loxP-flanked MDR allele was verified by Southern blot analysis of puri-
fied B cells derived from MDRfl/+CD19-Cre mice (Figure 1E). To test whether
dLeu2 mRNA expression is affected upon deletion of miR-15a/16-1, purified
B cells from miR-15a/16-1/ and wild-type mice were tested for dLeu2
expression by RT-PCR, and in vivo deletion of the loxP-flanked miR-15a/16-
1 allele was verified by multiplex PCR analysis of purified B cells derived
from miR-15a/16-1fl/+CD19-Cre mice (Figure 1F) (for primer sequences, see
Supplemental Information). All experiments with mice were approved by the
Institutional Animal Care and Use Committee (IACUC) of Columbia University,
and all experiments conformed to the corresponding relevant regulatory
standards.
Event-free Survival and Statistical Analysis
Tumor watch studies were conducted on animals in a 129/Sv-C57BL/6mixed
background (i.e., the first and second backcross generations). Mice were
monitored for tumor incidence biweekly and were sacrificed when visibly ill.
Within each transgenic line, comparable numbers of age-matched wild-type
littermates controlled for possible differences in tumor incidence. Animals
were monitored for up to 20 months. Statistical analysis was performed on
the Prism 5 software program (GraphPad, San Diego, CA) using Kaplan-Meier
cumulative survival and the log-rank (Mantel-Cox) test to determine whether
differences were significant (Figure 4B). The c2 test was used to compare
B-lymphoproliferation incidence between the different genotypes of the MDR
and miR-15a/16-1 cohorts (Figures 4A and 5B).
IgM-Stimulation Assays
Purified B cells from miR-15a/16-1/ or MDR/ and wild-type mice were
cultured at a density of 1.5 3 106 cells/ml in RPMI medium plus 10% FBS
with 15 mg/ml goat-anti-mouse Fab fragments for up to 48 hr (Jackson Immu-
notech). For detection of pRb and miR-15a/16-1 predicted target proteins,
cells were harvested at specific time points after stimulation, washed with
phosphate-buffered saline, and stored as frozen pellets to enable simulta-
neous lysis of the samples for western blot analysis.
Doxycycline-Inducible miR-15a/16-1 and DLEU2 Expression
in a 13q14/ CLL Cell Line
DNA fragments encoding either miR-15a/16-1 or the exonic sequence of
DLEU2 were inserted into the multiple cloning site of a doxycycline-inducible
vector (Bornkamm et al., 2005). This vector allows constitutive expression of
a bicistronic expression cassette encoding the doxycycline-sensitive reverse
tetracycline controlled transactivator rtTA2S-M2 and a Tet repressor-KRAB
fusion protein (tTSKRAB)(silencer) located downstream of an internal ribosomal
entry site. miR-15a/16-1 or DLEU2 are expressed from the bidirectional
promoter Ptetbi-1, which allows simultaneous expression of those genes along
with GFP that serves as surrogate marker for expression. The corresponding
vectors were stably transfected into the 13q14/ I83E95 cell line.
I83E95 cellswere cultured in 20%FCS-IMDMmedia at 0.5 to 13106 cells/ml
density. Cells were electroporated (500 mF/220 V) and subsequently selected
for the presence of the plasmids with hygromycin (250 mg/ml) for 12 days.
Inducibility was assessed 24 hr after doxycycline addition by measuring GFP
levels flow-cytometrically, DLEU2 transcript levels by RT-PCR and Northern
blot, and miR-15a/16-1 levels by Q-RT-PCR and Northern blot.
miR-15a/16-1 Computational Target Prediction
Precompiled miRNA target predictions for human 30UTR transcripts were
downloaded from the respective website for each of the four algorithms: Pictar
(http://pictar.mdc-berlin.de/), TargetScan (release 5.0, conserved sites, http://
targetscan.org), Miranda (version 5, http://microrna.sanger.ac.uk/targets/v5),
RNA22 (http://cbcsrv.watson.ibm.com/rna22.html). The union of the predic-
tions by those algorithms was considered as the candidate miR-15a/16-1
target list.38 Cancer Cell 17, 28–40, January 19, 2010 ª2010 Elsevier Inc.BrdU-Incorporation Assay
For measurement of DNA synthesis in I83E95 cells or mouse B cells, cells were
incubated with BrdU for 30 min at specific time points after the start of the
culture, and immediately harvested and fixed. BrdU incorporation and DNA
content were analyzed with the APC BrdU flow kit (Becton Dickinson). The
cell suspensions were analyzed on a FACSCalibur using CellQuest software.
ACCESSION NUMBERS
Gene expression data have been deposited in the Gene Expression Omnibus
(GEO) database with accession number GSE18866.
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